365 related articles for article (PubMed ID: 12480560)
61. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
Patel VC; Lee S; McPhail MJW; Da Silva K; Guilly S; Zamalloa A; Witherden E; Støy S; Manakkat Vijay GK; Pons N; Galleron N; Huang X; Gencer S; Coen M; Tranah TH; Wendon JA; Bruce KD; Le Chatelier E; Ehrlich SD; Edwards LA; Shoaie S; Shawcross DL
J Hepatol; 2022 Feb; 76(2):332-342. PubMed ID: 34571050
[TBL] [Abstract][Full Text] [Related]
62. Additional L-Carnitine Reduced the Risk of Hospitalization in Patients with Overt Hepatic Encephalopathy on Rifaximin.
Kubota K; Uojima H; Shao X; Iwasaki S; Hidaka H; Wada N; Nakazawa T; Shibuya A; Kako M; Koizumi W
Dig Dis; 2022; 40(3):313-321. PubMed ID: 34348263
[TBL] [Abstract][Full Text] [Related]
63. Rifaximin for the treatment of hepatic encephalopathy.
Mullen K; Prakash R
Expert Rev Gastroenterol Hepatol; 2010 Dec; 4(6):665-77. PubMed ID: 21108586
[TBL] [Abstract][Full Text] [Related]
64. Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose.
Lanthier PL; Morgan MY
Gut; 1985 Apr; 26(4):415-20. PubMed ID: 3979914
[TBL] [Abstract][Full Text] [Related]
65. [Hepatic encephalopathy and liver transplantation].
Fehérvári I; Nemes B; Görög D; Gerlei Z; Kóbori L
Magy Seb; 2012 Apr; 65(2):58-62. PubMed ID: 22512880
[TBL] [Abstract][Full Text] [Related]
66. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
[TBL] [Abstract][Full Text] [Related]
67. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis.
Blanc P; Daures JP; Rouillon JM; Peray P; Pierrugues R; Larrey D; Gremy F; Michel H
Hepatology; 1992 Feb; 15(2):222-8. PubMed ID: 1531204
[TBL] [Abstract][Full Text] [Related]
68. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study.
Simón-Talero M; García-Martínez R; Torrens M; Augustin S; Gómez S; Pereira G; Guevara M; Ginés P; Soriano G; Román E; Sánchez-Delgado J; Ferrer R; Nieto JC; Sunyé P; Fuentes I; Esteban R; Córdoba J
J Hepatol; 2013 Dec; 59(6):1184-92. PubMed ID: 23872605
[TBL] [Abstract][Full Text] [Related]
69. Editorial: prolonged remission from hepatic encephalopathy with rifaximin.
Orr JG; Hudson M
Aliment Pharmacol Ther; 2015 Jan; 41(2):228. PubMed ID: 25511766
[No Abstract] [Full Text] [Related]
70. Rifaximin: an alternative for the treatment of hepatic encephalopathy.
Rigali VT
Conn Med; 2006 Sep; 70(8):499-501. PubMed ID: 17089807
[No Abstract] [Full Text] [Related]
71. Impact of rifaximin use for hepatic encephalopathy on the risk of early post-transplant infections in liver transplant recipients.
Sun HY; Wagener M; Cacciarelli TV; Singh N
Clin Transplant; 2012; 26(6):849-52. PubMed ID: 22432742
[TBL] [Abstract][Full Text] [Related]
72. [A clinical comparative study of crystalline pure lactulose and powder pure lactitol in portasystemic encephalopathy of cirrhotic patients].
Grandi M; Sacchetti C; Pederzoli S; Celani MF
Minerva Gastroenterol Dietol; 1991; 37(4):225-30. PubMed ID: 1805974
[TBL] [Abstract][Full Text] [Related]
73. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
74. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.
Mullen KD; Sanyal AJ; Bass NM; Poordad FF; Sheikh MY; Frederick RT; Bortey E; Forbes WP
Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1390-7.e2. PubMed ID: 24365449
[TBL] [Abstract][Full Text] [Related]
75. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A
Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713
[TBL] [Abstract][Full Text] [Related]
76. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
[TBL] [Abstract][Full Text] [Related]
77. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study.
Morgan MY; Alonso M; Stanger LC
J Hepatol; 1989 Mar; 8(2):208-17. PubMed ID: 2654285
[TBL] [Abstract][Full Text] [Related]
78. [Intestine specific broad spectrum antibiotic. Rifaximin: therapy option in hepatic encephalopathy].
MMW Fortschr Med; 2014 Feb; 156(3):64-5. PubMed ID: 24938070
[No Abstract] [Full Text] [Related]
79. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy?
Butt NI; Butt UI; Kakar AATK; Malik T; Siddiqui AM
J Coll Physicians Surg Pak; 2018 Feb; 28(2):115-117. PubMed ID: 29394969
[TBL] [Abstract][Full Text] [Related]
80. Improvement of sleep architecture parameters in cirrhotic patients with recurrent hepatic encephalopathy with the use of rifaximin.
Bruyneel M; Sersté T; Libert W; van den Broecke S; Ameye L; Dachy B; Mulkay JP; Moreno C; Gustot T
Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):302-308. PubMed ID: 27977438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
